Colt CZ Group (CZG) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
13 Jun, 2025Executive summary
Achieved record H1 2024 revenues of CZK 9,690m (up 41.2% y-o-y) and adjusted EBITDA of CZK 1,981m (up 35.3% y-o-y), driven by Sellier & Bellot acquisition and US market recovery.
Sellier & Bellot acquisition completed in May 2024 for USD 703m, expanding the product portfolio and group scale.
Adjusted net profit declined 15.3% y-o-y to CZK 1,015m, mainly due to financial results and one-off adjustments.
Results exceeded half-year guidance, with strong Q2 performance and new contracts, including technology transfer to Ukraine.
Board of Directors strengthened with appointment of Radek Musil to represent the ammunition segment.
Financial highlights
Revenues increased 41.2% y-o-y to CZK 9,690m; adjusted EBITDA rose 35.3% to CZK 1,981m, both exceeding guidance.
Adjusted EPS was CZK 25 (down 28.4% y-o-y), impacted by share issuance and S&B acquisition effects.
Profit before tax fell 41.2% to CZK 794.8m; net profit dropped 41.7% to CZK 609.6m due to acquisition costs and higher depreciation.
Q2 2024 was the strongest quarter in company history, with units sold up 2.8% y-o-y and organic firearms revenue up 26.6%.
Total assets increased 79.8% to CZK 46.7bn; net financial debt rose to CZK 15.6bn (net leverage ratio 3.16x).
Outlook and guidance
FY 2024 guidance confirmed: revenues CZK 20,000–22,000m post-S&B consolidation, up to CZK 25bn pro-forma; adjusted EBITDA expected at CZK 3,300–3,800m, up to CZK 5.6bn pro-forma.
High quarterly seasonality anticipated in H2 2024, with Q4 expected to outperform Q3.
Capital expenditures for 2024 expected at CZK 1–1.2bn (approx. 5% of expected revenues).
Outlook subject to global demand, inflation, FX rates, and S&B integration.
Latest events from Colt CZ Group
- Net profit surged as ammunition growth offset U.S. firearms weakness; 2026 set for major gains.CZG
Q4 202525 Mar 2026 - Revenue and net profit surged, with acquisitions and bond issuance fueling future growth.CZG
Q3 202520 Nov 2025 - Ammunition-led growth and acquisitions drove higher revenues, with 2025 outlook reaffirmed.CZG
Q2 202518 Sep 2025 - Revenue up 51%, but net profit down on acquisition costs; guidance and leverage targets met.CZG
Q3 202413 Jun 2025 - Q1 2025 revenue up 50% and profit up 73%, with U.S. tariffs posing EBITDA risk.CZG
Q1 20259 Jun 2025 - 2024 revenue up 50.6% to CZK 22.4bn, with 2025 growth and profit distribution split expected.CZG
Q4 20249 Jun 2025